secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001140361-25-031041
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman
-----------------------------------------------------------------------------

- Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.
- R&D expenses fell to $3.3M from $9.8M due to NAVIGATE trial completion in Q1 2025.
- Cash and equivalents $13.8M at June 30; $10M line of credit from chairman closed July 8.
- Company expects sufficient funding to operate through June 30, 2026.
- NAVIGATE data at EASL showed belapectin reduced liver stiffness progression over 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/0001140361-25-031041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/ef20053791_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-031041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer